PMID- 22796288
OWN - NLM
STAT- MEDLINE
DCOM- 20130108
LR  - 20211203
IS  - 1769-664X (Electronic)
IS  - 0929-693X (Linking)
VI  - 19
IP  - 8
DP  - 2012 Aug
TI  - [Atopic dermatitis].
PG  - 882-5
LID - 10.1016/j.arcped.2012.05.020 [doi]
AB  - Atopic dermatitis (AD), or atopic eczema, is a pruriginous inflammatory 
      dermatosis with a genetic predisposition evolving in recurrent flare-ups on a 
      background of chronicity, affecting essentially infants and small children. The 
      clinical phenotype of AD results from interactions between genes and 
      susceptibility, a defect in the cutaneous barrier function (abnormalities in 
      filaggrin and the proteins of the epidermic differentiation complex) and 
      dysfunction of the innate and/or adaptive immune response. With its 
      multifactorial origin, it is dependent on the TH2 lymphocyte system, with a 
      tendency to produce immunoglobulin E (IgE) and the risk of asthma, rhinitis, or 
      allergic conjunctivitis define an atopic susceptibility. Staphylococcus aureus 
      colonization plays a vital role in the perpetuation of the inflammatory 
      phenomena. The disease often regresses in older children. Its prevalence is on 
      the rise in industrialized countries. Diagnosis is clinical, facilitated by 
      certain criteria initially proposed by Hanifin and Rajka and then simplified by 
      Williams. The allergological investigation is reserved for cases that are 
      stubborn, severe, or associated with respiratory symptoms. AD is a dermatosis 
      that evolves in erratic and often unpredictable flare-ups. AD flare-up treatment 
      is based on local corticosteroid therapy. Maintenance therapy attempts to correct 
      the cutaneous dryness with hydrating products whose efficacy has now been proven. 
      Optimal management includes the family's and/or the child's comprehension of the 
      treatment, explaining to them that the goal to reach is not only to relieve the 
      child, but also to attempt to modify the course of the disease. AD is thus a star 
      disease and a public health problem. The major progress made in the comprehension 
      of the physiopathological mechanisms of AD promise targeted therapies from new 
      biotechnologies.
CI  - Copyright (c) 2012. Published by Elsevier SAS.
FAU - Rybojad, M
AU  - Rybojad M
AD  - Hopital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France. 
      michel.rybojad@sls.aphp.fr
LA  - fre
PT  - Journal Article
TT  - La dermatite atopique.
DEP - 20120715
PL  - France
TA  - Arch Pediatr
JT  - Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
JID - 9421356
RN  - 0 (FLG protein, human)
RN  - 0 (Filaggrin Proteins)
RN  - 0 (Glucocorticoids)
RN  - 0 (Immunosuppressive Agents)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Dermatitis, Atopic/*complications/diagnosis/epidemiology/*therapy
MH  - Filaggrin Proteins
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Immunosuppressive Agents/therapeutic use
MH  - Infant
MH  - Prognosis
MH  - Remission, Spontaneous
MH  - Tacrolimus/therapeutic use
EDAT- 2012/07/17 06:00
MHDA- 2013/01/09 06:00
CRDT- 2012/07/17 06:00
PHST- 2011/12/09 00:00 [received]
PHST- 2012/05/31 00:00 [revised]
PHST- 2012/05/31 00:00 [accepted]
PHST- 2012/07/17 06:00 [entrez]
PHST- 2012/07/17 06:00 [pubmed]
PHST- 2013/01/09 06:00 [medline]
AID - S0929-693X(12)00250-3 [pii]
AID - 10.1016/j.arcped.2012.05.020 [doi]
PST - ppublish
SO  - Arch Pediatr. 2012 Aug;19(8):882-5. doi: 10.1016/j.arcped.2012.05.020. Epub 2012 
      Jul 15.